Experimental Drug Doubles Survival in Advanced Pancreatic Cancer Trial
Pancreatic cancer has long been one of the deadliest malignancies, with survival rates that have barely improved in decades. For people diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of receiving the diagnosis.
This cancer is often detected late because there is no effective screening test, and early-stage disease usually causes few or no symptoms. By the time patients develop jaundice or persistent abdominal pain, the tumor has often spread beyond the pancreas, sharply limiting treatment options.
Oncologists have relied mainly on intensive chemotherapy regimens to slow the disease, but these drugs frequently lose effectiveness as cancer cells develop resistance. The treatments are also highly toxic, damaging healthy tissue and leaving many patients too weak to continue therapy.
Why pancreatic tumors are so hard
The biology of pancreatic cancer is a major reason it is so difficult to treat. More than 90% of tumors carry mutations in a gene called KRAS, which encodes a protein that acts like an on-off switch for cell growth and division.
When KRAS is mutated, this molecular switch becomes stuck in the “on” position, driving uncontrolled cell growth and fueling tumor spread. For decades, researchers tried and failed to design drugs that could directly bind to KRAS and switch it off.
The protein’s surface is unusually smooth, offering none of the usual pockets that medicines can latch onto. This led many scientists to label KRAS “undruggable,” forcing clinicians to fall back on broad chemotherapy instead of precise, targeted therapies.
How daraxonrasib works
A new experimental drug called daraxonrasib is now challenging that long-held assumption. Taken as a once-daily pill, daraxonrasib does not attach directly to KRAS but instead binds to cyclophilin A, a helper molecule that assists proteins in folding into their final three-dimensional shapes.
By forming a complex with cyclophilin A, the drug indirectly locks onto active KRAS and interrupts its ability to send growth signals inside cancer cells. In effect, it shuts down the main engine driving the vast majority of pancreatic tumors.
The developer, Revolution Medicines, reported Phase 3 trial results on May 31, 2026, from a study of 500 patients with metastatic pancreatic cancer who had already received previous treatment. Participants were randomly assigned to receive either daraxonrasib or standard chemotherapy.
Trial results and side effects
According to the company’s data, daraxonrasib nearly doubled median overall survival, from 6.7 months with chemotherapy to 13.2 months with the new drug. The treatment was associated with a 60% reduction in the risk of death compared with standard care.
The most frequent side effect was a pronounced skin rash, reported in more than 86% of patients taking the drug. Many participants also experienced stomatitis, or painful swelling and sores in the mouth, along with diarrhea, nausea, and vomiting.
Despite these problems, patients taking daraxonrasib were less likely to discontinue treatment because of severe adverse events than those receiving chemotherapy. Quality-of-life assessments indicated better pain control and improved daily functioning in the targeted-therapy group.
What comes next for patients
The success of daraxonrasib shows that even long-dismissed targets like KRAS can become vulnerable through innovative drug design. By targeting the core mutation that drives most pancreatic cancers, the therapy offers a more precise approach than conventional chemotherapy.
The next major step is regulatory review. Revolution Medicines is expected to submit the Phase 3 data to the U.S. Food and Drug Administration and other regulators worldwide to seek formal approval for use in metastatic pancreatic cancer.
Because late-stage pancreatic cancer is so difficult to treat, medicines that demonstrate a clear survival advantage often qualify for expedited or priority review. If regulators grant approval through such a pathway, the drug could reach oncology clinics within months.
Experts anticipate that daraxonrasib will also be tested in combination with other targeted drugs, immunotherapies, or chemotherapy. The goal will be to prevent or delay resistance, a common problem as tumors evolve under the pressure of treatment.
For patients and clinicians, this development signals a possible turning point in a field that has seen few major advances. While daraxonrasib is not a cure, doubling survival in advanced disease represents meaningful extra time, often with a better quality of life.
Researchers hope that this first success against KRAS-driven pancreatic cancer will open the door to more personalized therapies. If future trials confirm the benefit and refine dosing and combination strategies, targeted drugs may gradually reshape the standard of care for this devastating disease.
